sofosbuvir/velpatasvir (Epclusa®)

Reference No. 2417

Publication date:

21/11/2016

Appraisal information

sofosbuvir/velpatasvir (Epclusa®) 400 mg/100 mg film-coated tablet

Company:	Gilead Sciences Ltd
BNF category:	Infections
NMG meeting date:	05/10/2016
AWMSG meeting date:	09/11/2016

Submission Type:	Directed
Status:	Superseded
Advice No:	3116
Ratification by Welsh Government:	18/11/2016

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA430) NICE GUIDANCE ISSUED JANUARY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation (FAR)

Download

sofosbuvir-velpatasvir (Epclusa) 2417 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

sofosbuvir-velpatasvir (Epclusa) 2417 ASAR

Clinical Expert (CE) Summary

Download

sofosbuvir-velpatasvir (Epclusa) 2417 CE summary